These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12970151)

  • 21. Systemic treatment of hepatocellular carcinoma.
    Treiber G
    Dig Dis; 2001; 19(4):311-23. PubMed ID: 11935091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin analogs and hepatocellular carcinoma: Not dead yet?
    Raftery L; O'Neil BH
    Cancer Biol Ther; 2009 Nov; 8(21):2040-1. PubMed ID: 19823044
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature.
    Gill ML; Atiq M; Sattar S; Khokhar N
    J Pak Med Assoc; 2005 Apr; 55(4):135-8. PubMed ID: 15918622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inhibition effects of octreotide on the growth of hepatocellular carcinoma in vitro and in vivo].
    Wang C; Tang C; Tang L
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1194-7. PubMed ID: 11769709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
    [No Abstract]   [Full Text] [Related]  

  • 26. Octreotide: no benefit in advanced liver cancer.
    Tilstone C
    Lancet Oncol; 2007 Feb; 8(2):103. PubMed ID: 17288044
    [No Abstract]   [Full Text] [Related]  

  • 27. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
    Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
    Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide.
    Wang M; Shan F; Zou Y; Sun X; Zhang ZR; Fu Y; Gong T
    J Control Release; 2016 May; 230():45-56. PubMed ID: 27040814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma.
    Deming DA; Stella AL; Holen KD; Ku G; O'Reilly EM
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):468-72; discussion 472-4. PubMed ID: 16167024
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.
    Hua YP; Yin XY; Peng BG; Li SQ; Lai JM; Liang HZ; Liang LJ
    Chemotherapy; 2009; 55(5):312-20. PubMed ID: 19590186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation.
    Lersch C; Schmelz R; Erdmann J; Hollweck R; Schulte-Frohlinde E; Eckel F; Nader M; Schusdziarra V
    Hepatogastroenterology; 2004; 51(58):1099-103. PubMed ID: 15239254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.
    Ji XQ; Ruan XJ; Chen H; Chen G; Li SY; Yu B
    Med Sci Monit; 2011 Aug; 17(8):RA169-176. PubMed ID: 21804474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
    Guo TK; Hao XY; Ma B; Yang KH; Li YP; Li HL; Gu YH; Cai H; Liu YL; Li Y; Zhan WP
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1685-92. PubMed ID: 19536563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
    Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-TACE combination therapy of heparin and octreotide results in decreased tumor metastasis in extrahepatic tumorigenesis.
    Jia W; Feng K; Fan P; Fan G; Yang S; Zhang T; Wei Q; Qian L
    Cell Biochem Biophys; 2012 Jan; 62(1):35-40. PubMed ID: 21822978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide for cancer of the liver and biliary tree.
    Kouroumalis EA
    Chemotherapy; 2001; 47 Suppl 2():150-61. PubMed ID: 11275708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
    Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
    Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
    Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Systemic treatment for hepatocellular carcinoma].
    Spangenberg HC; Zuber-Jerger I; Thimme R; Blum HE; Von Weizsäcker F
    Zentralbl Chir; 2003 Nov; 128(11):906-10. PubMed ID: 14669110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete regression of hepatocellular carcinoma under tamoxifen.
    Castéra L; Boige V; Rocher L; Duclos-Vallée JC; Fabre M; Buffet C
    Am J Gastroenterol; 2000 Mar; 95(3):827-9. PubMed ID: 10710095
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.